Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/20/2005CA2188508C Gonadotropins with non-native disulfide bridges
12/18/2005CA2509049A1 Production of mutant strain of aspergillus fumigatus, method and assay for inhibiting siderophore biosynthesis and diagnostic method for detecting likely aspergillus fumigatus infection
12/15/2005WO2005119266A1 Sr-a antagonists
12/15/2005WO2005119264A1 Method for screening and compositions for treating cancers
12/15/2005WO2005118886A2 Stable peptide mimetic of hiv gp41 fusion intermediate
12/15/2005WO2005118876A2 Egfr mutations
12/15/2005WO2005118840A2 Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
12/15/2005WO2005118799A1 Ovine hyaluronidase
12/15/2005WO2005118786A2 Splice variants of peptide yy, neuropeptide y, pancreatic peptide y and amylin, and uses thereof
12/15/2005WO2005118782A2 Methods of promoting cardiac cell proliferation
12/15/2005WO2005118672A1 Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs
12/15/2005WO2005118641A1 Splice variant of unc5h2
12/15/2005WO2005118637A1 Treatment of inflammatory conditions
12/15/2005WO2005118636A2 Tgf derepressors and uses related thereto
12/15/2005WO2005118634A2 Helical peptidomimetics with enhanced activity against beta-amyloid production
12/15/2005WO2005118630A2 Peptides for the treatment of diabetes
12/15/2005WO2005118629A1 BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
12/15/2005WO2005118627A2 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
12/15/2005WO2005118626A2 Peptides for inducing a ctl and/or htl response to hepatitis c virus
12/15/2005WO2005118623A1 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member
12/15/2005WO2005118619A1 Dipeptide exhibiting antihypertensive action
12/15/2005WO2005118618A1 Substituted propane phosphinic acid derivatives
12/15/2005WO2005118614A1 Methods and compositions for treating neuropathic pain
12/15/2005WO2005118613A2 Antibacterial amide macrocycles
12/15/2005WO2005118611A2 Microutrophin and uses thereof
12/15/2005WO2005118020A1 Surface coating comprising bioactive compound
12/15/2005WO2005118016A1 Medical device comprising a biologically active agent
12/15/2005WO2005117992A2 Controlled delivery of therapeutic compounds
12/15/2005WO2005117989A1 Drugs for the prevention or treatment of immunodeficiencies, autoimmune diseases or for the induction of immune tolerance
12/15/2005WO2005117979A2 Use of il-17 in the treatment of fertility-related disorders
12/15/2005WO2005117955A1 Treatment of atopic dermatitis with unglycosylated alpha one-antitrypsin
12/15/2005WO2005117954A2 Compositions and methods for treatment of neovascular diseases
12/15/2005WO2005117952A2 Treatment methods utilizing albumin-binding proteins as targets
12/15/2005WO2005117951A1 Methods and formulations for increasing intestinal function
12/15/2005WO2005117950A2 Regulation of glucose and insulin levels by gnt-4 glycosyltransferase activity
12/15/2005WO2005117949A1 Stabilized interferon liquid formulations
12/15/2005WO2005117948A1 Method of stabilizing proteins
12/15/2005WO2005117947A1 Use of the foamy virus bet protein for inactivating apobec
12/15/2005WO2005117946A1 Treatment of amyotrophic lateral sclerosis
12/15/2005WO2005117945A1 Methods of using il-1 antagonists to treat autoinflammatory disease
12/15/2005WO2005117944A2 Hsp20 inhibits amyloidogenesis and neurotoxicity
12/15/2005WO2005117943A2 Biomarkers for monitoring inhibition of impdh pathway
12/15/2005WO2005117942A2 Methods for encapsulation of biomacromolecules in polymers
12/15/2005WO2005117941A2 Methods and compositions for the treatment of polycystic diseases
12/15/2005WO2005117940A2 Cell death modulation via antagonists of fasl and fas activation
12/15/2005WO2005117939A2 Use of gpcr54 ligands for the treatment of infertility
12/15/2005WO2005117938A2 Methods of treating ocular conditions
12/15/2005WO2005117937A2 Alpha-1- acid glycoprotein for the treatment of diabetes
12/15/2005WO2005117936A2 Method for enhancing or inhibiting insulin-like growth factor-i
12/15/2005WO2005117935A1 Multiple agent therapy for sexual dysfunction
12/15/2005WO2005117934A1 Sustained release composition
12/15/2005WO2005117933A1 Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition
12/15/2005WO2005117932A1 Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents
12/15/2005WO2005117931A2 Glut1 transporters expressed in cancer cells
12/15/2005WO2005117930A2 Use of thioredoxin measurements for diagnostics and treatments
12/15/2005WO2005117929A1 Microbial biosurfactants as agents for controlling pests
12/15/2005WO2005117928A1 Compositions and methods for the treatment of skin cancer
12/15/2005WO2005117927A2 Tissue protective cytokines with an extended therapeutic window
12/15/2005WO2005117916A1 Treatment with cisplatin and an egfr-inhibitor
12/15/2005WO2005117915A1 Treatment with oxaliplatin and an egfr-inhibitor
12/15/2005WO2005117912A1 Methods for treating bleeding disorders using sulfated polysaccharides
12/15/2005WO2005117895A2 Compositions comprising meloxicam
12/15/2005WO2005117848A2 Vascular targets for detecting, imaging and treating neoplasia or neovasculature
12/15/2005WO2005117810A1 External preparation for the skin
12/15/2005WO2005117753A1 Medical devices composed of porous metallic materials for delivering biolgically active materials
12/15/2005WO2005117584A2 Improved transmucosal delivery of peptides and proteins
12/15/2005WO2005107785A3 Human complement c3 derivates with cobra venom factor-like function
12/15/2005WO2005103263B1 Bone delivery conjugates and method of using same to target proteins to bone
12/15/2005WO2005097177A8 Use of collagenase to facilitate guide wire crossing in total arterial occlusions
12/15/2005WO2005090570A9 Therapeutic compositions and methods for treating diseases that involve angiogenesis
12/15/2005WO2005082396A3 Use of mda-7 to inhibit infection by pathogenic organisms
12/15/2005WO2005079848A3 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
12/15/2005WO2005079506A3 Systemic immune activation method using nucleic acid-lipid complexes
12/15/2005WO2005077093A3 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
12/15/2005WO2005075666A3 Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps)
12/15/2005WO2005072764A3 Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
12/15/2005WO2005063809A8 Nature-identical erythropoietin
12/15/2005WO2005062874A3 Compounds and compositions for delivering active agents
12/15/2005WO2005060541A3 Peptides and methods for inducing cellular resistance to infection
12/15/2005WO2005058959A3 Treatment of viral infections
12/15/2005WO2005056572A3 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
12/15/2005WO2005046592A3 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
12/15/2005WO2005035088A3 Method for preparing small spherical by controlled phase separation
12/15/2005WO2005033267A3 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof
12/15/2005WO2005021706A3 Delivery of compounds with rehydrated blood cells
12/15/2005WO2005021556A3 Modified protease inhibitors
12/15/2005WO2004105699A3 Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
12/15/2005WO2004100864A3 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases
12/15/2005WO2004083258A3 Branched water-soluble polymers and their conjugates
12/15/2005WO2004073633A3 Methods and compositions for modulating the development of stem cells
12/15/2005WO2004066931A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
12/15/2005WO2004064787A3 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
12/15/2005WO2004056317A8 Compositions for the treatment and prevention of nephropathy
12/15/2005WO2004043403A3 Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
12/15/2005WO2004029072A3 PrPsc -INTERACTING MOLECULES AND USES THEREOF
12/15/2005WO2004014313A3 Combination pharmaceutical agents as inhibitors of hcv replication
12/15/2005WO2004000211A3 Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
12/15/2005WO2004000102A3 Method for predicting response to epidermal growth factor receptor-directed therapy
12/15/2005WO2003063759A3 Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
12/15/2005WO2003062370A3 Multimeric proteins and methods of making and using same
1 ... 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 ... 3163